Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.

by Li Shen, Michael Ciesielski, Swathi Ramakrishnan, Kiersten M Miles, Leigh Ellis, Paula Sotomayor, Protul Shrikant, Robert Fenstermaker, Roberto Pili
Published 2012-01-01